Rheumatoid Arthritis

Taking an integrative approach to management by using a combination of therapies and lifestyle changes to treat the whole person can have benefits for many conditions, such as cardiovascular disease and diabetes. How does this approach fit in with the management of rheumatoid arthritis? Test your knowledge with this quiz.

Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.

A trial comparing a 1-week methotrexate hold following seasonal influenza vaccination against the standard 2-week hold among patients with rheumatoid arthritis using methotrexate suggests there were no significant differences in positive vaccine response with either approach.

For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."

The median time-to-remission was longer for women compared to men.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

The importance of patient-reported outcome measures (PROMs) for assessing the impact of diseases on patients and their response to treatment continues to grow. Test your knowledge of the role of the Rheumatoid Arthritis Impact of Disease (RAID) score in this quiz.

While approximately 1 in 5 patients with RA went undiagnosed during the early stage of the COVID-19 pandemic, time to first rheumatology assessment and DMARD prescription were not impacted.

“Most thyroid diseases and rheumatoid arthritis are chronic diseases, and unfortunately, early signs of thyroid dysfunction are not specific and are often overshadowed by clinical manifestations of other diseases."

Patients with rheumatoid arthritis had significantly higher levels of IgA anti-Pc-p27 antibodies and higher levels of IgG anti-Pc-p27 antibodies when compared with healthy controls.

Muscle wasting is a common characteristic associated with rheumatoid arthritis. Test your knowledge of muscle wasting in rheumatoid arthritis with this quiz.

John Cush, MD, discusses his CCR West presentation “Rheumatology Year in Review: 2022.” 

John Cush, MD, discusses his presentation “Rheumatoid Arthritis: How Early is Too Early to Diagnose and Treat?”

People with rheumatoid arthritis are also more likely to live with other chronic conditions, but specific ones vary by race. Test your knowledge of how race affects multimorbidity in this quiz.

Recent findings suggest that methotrexate reduces humoral vaccination response against COVID-19 in older, but not younger, patients with rheumatoid arthritis.

“Failed or inadequate response to disease-modifying antirheumatic drugs (DMARDs) is associated with poor prognosis," investigators noted.

The study examined ozoralizumab without concomitant therapy, as methotrexate cannot be given to all patients with rheumatoid arthritis due to inadequate efficacy and tolerability.

How much do you know about the Rheumatic Disease Report Card and how it relates to your practice? Test your knowledge with this quiz.